FDA Approves Pfizer-BioNTech's XFG-Adapted COVID-19 Vaccine for the 2026-27 Season

The U.S. Food and Drug Administration has approved Pfizer and BioNTech's updated COVID-19 vaccine formula, Comirnaty XFG, for the 2026-2027 respiratory virus season, the companies announced. The approval covers adults 65 and older and people ages 5 through 64 with at least one underlying condition that puts them at high risk of severe COVID-19, and the companies said shipping of the new formula began immediately, with doses expected at pharmacies, hospitals, and clinics across the country within days.

Illustration: a vaccine vial and syringe on a clinical tray, representing the updated XFG-adapted COVID-19 vaccine.

What Happened

Pfizer and BioNTech announced that the FDA has granted approval to the supplemental biologics license application for their 2026-2027 COVID-19 vaccine formula, which targets the XFG variant of the coronavirus. The announcement marks the annual update of the vaccine's composition — a now-routine process, much like the yearly flu shot reformulation, that matches the vaccine to the variants regulators expect to dominate the coming season.

The approval is narrower than the broad authorizations of the pandemic's early years. It covers adults 65 years and older, as well as individuals ages 5 through 64 who have at least one underlying condition that puts them at high risk for severe COVID-19 outcomes — a population-based, risk-stratified approach that U.S. regulators have increasingly favored for COVID boosters.

The FDA based its approval on the companies' existing body of clinical, nonclinical, and real-world evidence supporting Comirnaty's safety and effectiveness, according to the announcement. That evidence was supplemented with manufacturing and nonclinical data showing that the XFG-adapted formula generates strong immune responses against currently circulating variants — including XFG itself and its offshoots XFG.1.1, NB.1.8.1, PQ.17, and PQ.2.8.1.

Importantly for the rollout, the companies said shipping for the updated vaccine began immediately after approval, with availability expected at pharmacies, hospitals, and clinics across the country in the coming days. That rapid distribution means the new formula should reach arms well before the traditional winter peak of respiratory viruses.

Background

The approval continues one of the most consequential chapters in the history of vaccinology. Comirnaty, built on BioNTech's mRNA platform, became the first COVID-19 vaccine authorized in the United States and has since been adapted multiple times as the virus evolved — from the original strain, through the Omicron-era bivalent and monovalent formulas, to this season's XFG target. The companies report that more than 5 billion doses of Comirnaty have been distributed globally to date, citing a continued favorable safety and efficacy profile supported by real-world evidence alongside clinical, nonclinical, pharmacovigilance, and manufacturing data.

The selection of XFG as this season's target follows FDA guidance identifying it as the preferred vaccine composition for the United States beginning in fall 2026, the companies said. Each year, regulators and manufacturers walk a tightrope: choose the variant most likely to circulate months in advance, then manufacture at scale. The data supporting this year's pick showed the XFG-adapted formula producing strong immune responses not only against XFG but against a family of currently circulating variants — XFG.1.1, NB.1.8.1, PQ.17, and PQ.2.8.1 — which gives the formula a margin of safety if the variant mix shifts during the season.

BioNTech serves as the marketing authorization holder for the Pfizer-BioNTech COVID-19 vaccine and its adapted formulas across the U.S., EU, U.K., and other markets, while Pfizer handles commercialization in many territories. The mRNA platform that made the rapid seasonal updates possible is the same technology the companies have extended into other vaccines, including combination and cancer-vaccine candidates — though those remain investigational.

The regulatory path this year also reflects how COVID vaccination has been normalized. The supplemental biologics license application builds on the accumulated evidence base rather than starting from scratch, which is why the FDA could act on the existing record of clinical, nonclinical, and real-world data. It is, in effect, the same regulatory logic that governs annual flu vaccine strain updates.

Illustration: scientists reviewing vaccine data on large monitors in a modern laboratory.

Why It Matters

The approval matters first because COVID-19 has not gone away. The virus continues to circulate and evolve, producing seasonal waves that send the most vulnerable — older adults and people with underlying conditions such as heart disease, diabetes, or weakened immune systems — to hospitals in large numbers each winter. An updated vaccine matched to the currently circulating XFG family of variants is the most direct tool available to blunt that toll.

It matters, too, because timing is everything with seasonal vaccination. The companies' decision to begin shipping immediately, with pharmacy and clinic availability expected within days, gives the high-risk population a window to be vaccinated before holiday travel and indoor gatherings drive transmission upward. Public-health campaigns have repeatedly shown that early availability — not just efficacy — determines how much of a season's hospital burden vaccination actually prevents.

The targeted authorization also signals the settled shape of U.S. COVID vaccine policy: annual updates aimed at those most likely to suffer severe outcomes, rather than universal campaigns. That approach concentrates protection where the data show the greatest benefit, though it also places more responsibility on individuals to know whether they qualify — adults 65 and older, plus younger people with at least one high-risk condition — and to seek out the shot.

Finally, the approval is a milestone for the mRNA platform itself. The ability to redesign, manufacture, and distribute an updated vaccine in time for a single respiratory season was science fiction a decade ago. That the 2026-27 update arrived through a supplemental application — building on more than 5 billion distributed doses of safety and effectiveness data — shows how thoroughly the technology has moved from emergency innovation to established public-health infrastructure.

What Happens Next

The immediate next step is logistics. With shipping underway, the updated vaccine should appear at pharmacies, hospitals, and clinics across the country in the coming days, according to the companies. Pharmacies and health systems will fold the new formula into their fall vaccination campaigns, typically offered alongside flu shots.

Public-health agencies are expected to issue their own recommendations on who should receive the updated vaccine and when, and clinicians will counsel patients — particularly those 65 and older and those with underlying conditions — about the benefits and the known safety profile. Comirnaty carries important safety information, including the possibility of severe allergic reactions, which typically occur within minutes to an hour of vaccination. Myocarditis and pericarditis have been reported following mRNA COVID-19 vaccination, most commonly in male individuals ages 12 through 24, with symptoms generally appearing within a week of vaccination, according to the product information. Individuals with weakened immune systems may have a reduced immune response, and commonly reported side effects include injection-site reactions, fatigue, headache, muscle pain, chills, fever, and nausea.

Regulators will keep watching the variant landscape. If XFG's relatives fade and a different variant rises, the strain-selection process will begin again for the 2027-28 formula — the annual cycle that now defines COVID vaccination. Researchers will also be monitoring real-world effectiveness data through the season to confirm that the immune responses seen in the supporting data translate into protection against hospitalization and death.

Globally, the XFG-adapted formula will move through other regulators in the coming weeks, with BioNTech as marketing authorization holder across the EU, U.K., and other markets. The U.S. approval, as usual, is likely to set the tempo for the rest of the world's seasonal updates.

Illustration: a bright pharmacy clinic preparing for the seasonal vaccination campaign.

Sponsored: explore today's featured sponsored offers

FAQ

1. What did the FDA approve?
The FDA approved the supplemental biologics license application for Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula, Comirnaty XFG, which targets the XFG variant. The approval covers adults 65 and older and individuals ages 5 through 64 with at least one underlying condition that puts them at high risk of severe COVID-19, according to the companies' announcement.

2. Why was the XFG variant chosen?
The companies said the selection follows FDA guidance identifying XFG as the preferred vaccine composition for the U.S. beginning in fall 2026. Supporting data showed the XFG-adapted formula generates strong immune responses against currently circulating variants, including XFG, XFG.1.1, NB.1.8.1, PQ.17, and PQ.2.8.1.

3. When will the updated vaccine be available?
Shipping began immediately after approval, and the companies said the vaccine is expected to be available at pharmacies, hospitals, and clinics across the country in the coming days — ahead of the winter respiratory virus season.

4. What are the known side effects?
Commonly reported side effects include injection-site reactions, fatigue, headache, muscle pain, chills, fever, and nausea, according to the product information. Severe allergic reactions are possible, typically within minutes to an hour of vaccination. Myocarditis and pericarditis have been reported following mRNA COVID-19 vaccination, most commonly in males ages 12 through 24, with symptoms generally appearing within a week. Immunocompromised individuals may have a reduced immune response.

5. How many doses of Comirnaty have been given worldwide?
More than 5 billion doses of Comirnaty have been distributed globally to date, the companies said, citing a continued favorable safety and efficacy profile supported by real-world evidence alongside clinical, nonclinical, pharmacovigilance, and manufacturing data.

Sources

• The Educated Patient — "FDA Approves Pfizer-BioNTech's XFG-Adapted COVID-19 Vaccine for 2026-2027 Season," October 2026.
• Pfizer / BioNTech company announcement — FDA approval of the supplemental biologics license application for Comirnaty XFG (via GlobeNewswire), October 2026.
• FDA product information — Comirnaty safety information, including allergic reactions, myocarditis/pericarditis, and common side effects.